Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBAt the end of this week, I will complete another trip around the sun. This seemed like an appropriate time to provide you with updates on several columns I have shared in the past year. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, the…. Read more. September 27, 2024 News by Andrea Lobo.
Everything is harder with a relentless disease like IPF
WEB5 hours ago · I was diagnosed with IPF in 2016 and have been living in a state of limbo ever since. Sometimes my symptoms feel well-managed, but then there are periods that involve numerous trips to the hospital, appointments, and tests.Being a young adult with a lung disease that causes severe shortness of breath and exhaustion is …
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
WEB6 days ago · A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
WEBApr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
Top 10 Pulmonary Fibrosis Stories of 2021
WEBJan 3, 2022 · breathing exercises, Collagen turnover, esopremazole, MDM4, N115, pterostilbene, renin-angiotensin system, Salvianolic acid B, Top 10, TXR-1002, TXR-1007, Tyvaso, vitamin D. Pulmonary Fibrosis News counts down its top 10 most-read stories of 2021, noting what made each relevant for the PF community.
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
Exclusive Interview on Genentech’s Pulmonary Fibrosis Therapy, …
WEBNov 13, 2015 · by Patrícia Silva, PhD November 13, 2015. Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was one of the first two drugs to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung ...
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
WEBOct 28, 2022 · Earlier this year, final data from a Phase 2 clinical trial (NCT04419506) demonstrated that BI 1015550 slowed lung function decline in 147 IPF patients, ages 40 and older, regardless of whether they were receiving anti-fibrotic therapies. “We’re excited to build on the positive Phase 2 results so we can better understand the long-term efficacy, safety and tolerability of this ...